The financing presented yesterday could fund operations to potential approval of MOB-015 in the US, regardless of the outcome of the European study. This is positive given the current market conditions. However, this may become negative for the share price as it will become difficult to put a price on the stock (uncertainty about future dilution) and possibly selling pressure in connection to conversion.